Recordati’s OTC Sales Lifted by Acquisitions And Italy
Italy's Recordati enjoyed strong growth in its home market and abroad, lifting OTC group sales in 2019.
You may also be interested in...
Teva's Ratiopharm and Italy's Recordati have submitted applications to switch drugs from prescription-to-OTC status through EMA's centralised procedure. Given only four products have been switched centrally to date, a double reclassification would be unprecedented.
Recordati's new private-equity owners make their first move to strengthen the Italian firm's position in Europe's OTC market by grabbing Paris-based Laboratoires Tonipharm and its leading Ginkor brand.
Acquiring France's UPSA helped to lift Taisho's sales in the 12 months ended 31 March 2020, as its domestic Japanese business faltered.